Robert A Hegele

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8551269/publications.pdf

Version: 2024-02-01

779	51,516	2093	2439
papers	citations	100 h-index	197 g-index

809	809	809	44657
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	13.7	3,249
2	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
3	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	1.0	2,132
4	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
5	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet, The, 2000, 356, 279-284.	6.3	866
6	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
7	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
8	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
9	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	0.8	680
10	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult â€“ 2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	0.8	653
11	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
12	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	6.3	624
13	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518, 102-106.	13.7	581
14	Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. American Journal of Cardiology, 1993, 72, 171-176.	0.7	480
15	Hypertension Canadaâ€™s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
16	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	5.5	473
17	Hypertriglyceridemia: its etiology, effects and treatment. Cmaj, 2007, 176, 1113-1120.	0.9	443
18	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431

#	Article	IF	Citations
19	Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nature Genetics, 2010, 42, 684-687.	9.4	414
20	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
21	Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Current Opinion in Lipidology, 1996, 7, 69-76.	1.2	389
22	Narrative Review: Statin-Related Myopathy. Annals of Internal Medicine, 2009, 150, 858.	2.0	369
23	Plasma lipoproteins: genetic influences and clinical implications. Nature Reviews Genetics, 2009, 10, 109-121.	7.7	367
24	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	0.8	367
25	Kinase mutations in human disease: interpreting genotypeâ€“phenotype relationships. Nature Reviews Genetics, 2010, 11, 60-74.	7.7	330
26	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology,the, 2016, 4, 850-861.	5.5	329
27	Hypertension Canadaâ€™s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
28	Effects of Intensive Medical Therapy on Microemboli and Cardiovascular Risk in Asymptomatic Carotid Stenosis. Archives of Neurology, 2010, 67, 180.	4.9	318
29	Familial hypercholesterolaemia. Nature Reviews Disease Primers, 2017, 3, 17093.	18.1	315
30	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	1.0	303
31	Clinical review on triglycerides. European Heart Journal, 2020, 41, 99-109c.	1.0	286
32	Apolipoprotein Bâ€“Gene DNA Polymorphisms Associated with Myocardial Infarction. New England Journal of Medicine, 1986, 315, 1509-1515.	13.9	282
33	Effect on Blood Lipids of Very High Intakes of Fiber in Diets Low in Saturated Fat and Cholesterol. New England Journal of Medicine, 1993, 329, 21-26.	13.9	270
34	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
35	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
36	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262

#	Article	IF	Citations
37	Naringenin Prevents Dyslipidemia, Apolipoprotein B Overproduction, and Hyperinsulinemia in LDL Receptorâ€“Null Mice With Diet-Induced Insulin Resistance. Diabetes, 2009, 58, 2198-2210.	0.3	254
38	PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy. Diabetes, 2002, 51, 3586-3590.	0.3	246
39	Chylomicronaemiaâ€”current diagnosis and future therapies. Nature Reviews Endocrinology, 2015, 11, 352-362.	4.3	242
40	Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci. American Journal of Human Genetics, 2012, 90, 410-425.	2.6	239
41	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
42	Genetic determinants of plasma triglycerides. Journal of Lipid Research, 2011, 52, 189-206.	2.0	223
43	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
44	An siRNA-based functional genomics screen for theÂidentification of regulators of ciliogenesis and ciliopathyÂgenes. Nature Cell Biology, 2015, 17, 1074-1087.	4.6	215
45	LMNA is mutated in Hutchinson-Gilford progeria (MIMÂ176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIMÂ264090). Journal of Human Genetics, 2003, 48, 271-274.	1.1	205
46	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology, 2016, 32, S35-S65.	0.8	194
47	The complex molecular genetics of familial hypercholesterolaemia. Nature Reviews Cardiology, 2019, 16, 9-20.	6.1	193
48	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2010, 26, 249-258.	0.8	191
49	TMEM237 Is Mutated in Individuals with a Joubert Syndrome Related Disorder and Expands the Role of the TMEM Family at the Ciliary Transition Zone. American Journal of Human Genetics, 2011, 89, 713-730.	2.6	178
50	Sequencing of the Reannotated LMNB2 Gene Reveals Novel Mutations in Patients with Acquired Partial Lipodystrophy. American Journal of Human Genetics, 2006, 79, 383-389.	2.6	177
51	The transcription factor cyclic AMPâ€“responsive elementâ€“binding protein H regulates triglyceride metabolism. Nature Medicine, 2011, 17, 812-815.	15.2	174
52	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2439-2445.	1.1	174
53	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
54	Autosomal-Recessive Intellectual Disability with Cerebellar Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter Gene SLC39A8. American Journal of Human Genetics, 2015, 97, 886-893.	2.6	171

#	Article	IF	Citations
55	Abetalipoproteinemia: two case reports and literature review. Orphanet Journal of Rare Diseases, 2008, 3, 19.	1.2	168
56	Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics, 2013, 6, 400-408.	5.1	168
57	Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics, 1999, 22, 325-326.	9.4	166
58	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. Clinical Chemistry, 2015, 61, 231-238.	1.5	166
59	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
60	The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329.	1.2	162
61	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. Journal of Clinical Investigation, 2009, 119, 1042-50.	3.9	162
62	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology, 2011, 27, 635-662.	0.8	160
63	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes, 2016, 65, 1767-1778.	0.3	155
64	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	9.4	155
65	Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. Journal of Inherited Metabolic Disease, 2014, 37, 333-339.	1.7	154
66	Functional foods and dietary supplements for the management of dyslipidaemia. Nature Reviews Endocrinology, 2017, 13, 278-288.	4.3	154
67	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Canadian Journal of Cardiology, 2013, 29, 1553-1568.	0.8	153
68	Enzyme-Sensitive Magnetic Resonance Imaging Targeting Myeloperoxidase Identifies Active Inflammation in Experimental Rabbit Atherosclerotic Plaques. Circulation, 2009, 120, 592-599.	1.6	151
69	Severe Hypertriglyceridemia in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2589-2596.	1.8	147
70	Hutchinson-Gilford progeria syndrome. Clinical Genetics, 2004, 66, 375-381.	1.0	142
71	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	6.3	142
72	Noninvasive Phenotypes of Atherosclerosis. Stroke, 2004, 35, 649-653.	1.0	140

#	Article	IF	Citations
73	Genetic determinants of the metabolic syndrome. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 482-489.	3.3	138
74	Premature Atherosclerosis Associated With Monogenic Insulin Resistance. Circulation, 2001, 103, 2225-2229.	1.6	136
75	Severe hypertriglyceridemia is primarily polygenic. Journal of Clinical Lipidology, 2019, 13, 80-88.	0.6	136
76	Genetic determinants of statin intolerance. Lipids in Health and Disease, 2007, 6, 7.	1.2	134
77	Is raising HDL a futile strategy for atheroprotection?. Nature Reviews Drug Discovery, 2008, 7, 143-155.	21.5	129
78	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
79	HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infectious Diseases, The, 2007, 7, 787-796.	4.6	125
80	Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids in Health and Disease, 2008, 7, 3.	1.2	124
81	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	2.0	124
82	The Hepatic Nuclear Factor-1Î± G319S Variant Is Associated with Early-Onset Type 2 Diabetes in Canadian Oji-Cree1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1077-1082.	1.8	123
83	Thematic review series: Adipocyte Biology. Lipodystrophies: windows on adipose biology and metabolism. Journal of Lipid Research, 2007, 48, 1433-1444.	2.0	122
84	Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 2011, 88, 6-18.	2.6	122
85	Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circulation: Cardiovascular Genetics, 2010, 3, 39-46.	5.1	120
86	Plasma Homocyst(e)ine Concentration, But Not MTHFR Genotype, Is Associated With Variation in Carotid Plaque Area. Stroke, 1999, 30, 969-973.	1.0	118
87	Polygenic determinants of severe hypertriglyceridemia. Human Molecular Genetics, 2008, 17, 2894-2899.	1.4	118
88	Hypertriglyceridemia in the Genomic Era: A New Paradigm. Endocrine Reviews, 2015, 36, 131-147.	8.9	118
89	Common and Rare ABCA1 Variants Affecting Plasma HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1983-1989.	1.1	117
90	A Polymorphism of the Paraoxonase Gene Associated With Variation in Plasma Lipoproteins in a Genetic Isolate. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 89-95.	1.1	115

#	Article	IF	Citations
91	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	5.5	114
92	Regulation of Macrophage Cholesterol Efflux through Hydroxymethylglutaryl-CoA Reductase Inhibition. Journal of Biological Chemistry, 2005, 280, 22212-22221.	1.6	112
93	NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids in Health and Disease, 2005, 4, 16.	1.2	111
94	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2009, 25, 287-298.	0.8	111
95	HNF-1Â G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4614-4619.	3.3	110
96	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	8.9	110
97	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	5.5	109
98	Genetic bases of hypertriglyceridemic phenotypes. Current Opinion in Lipidology, 2011, 22, 247-253.	1.2	108
99	Hypertriglyceridemia. Nutrients, 2013, 5, 981-1001.	1.7	108
100	LipidSeq: a next-generation clinical resequencing panel for monogenic dyslipidemias. Journal of Lipid Research, 2014, 55, 765-772.	2.0	108
101	N-of-1 (Single-Patient) Trials for Statin-Related Myalgia. Annals of Internal Medicine, 2014, 160, 301-310.	2.0	106
102	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nature Reviews Cardiology, 2018, 15, 9-19.	6.1	105
103	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	0.8	105
104	Whole exome sequencing of familial hypercholesterolaemia patients negative forLDLR/APOB/PCSK9mutations. Journal of Medical Genetics, 2014, 51, 537-544.	1.5	104
105	Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels. Journal of Molecular Diagnostics, 2017, 19, 905-920.	1.2	104
106	SNP Judgments and Freedom of Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1058-1061.	1.1	103
107	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
108	The Heritability of Mammographically Dense and Nondense Breast Tissue. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 612-617.	1.1	101

#	Article	IF	Citations
109	Genetics of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 455.	1.5	100
110	Lipoprotein(a). Current Opinion in Lipidology, 2012, 23, 133-140.	1.2	99
111	Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. Genomics, 1988, 3, 230-236.	1.3	98
112	Recessive TRAPPC11 Mutations Cause a Disease Spectrum of Limb Girdle Muscular Dystrophy and Myopathy with Movement Disorder and Intellectual Disability. American Journal of Human Genetics, 2013, 93, 181-190.	2.6	98
113	Severe Hypertriglyceridemia With Pancreatitis. JAMA Internal Medicine, 2014, 174, 443.	2.6	97
114	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	0.6	97
115	The pathogenesis of atherosclerosis. Clinica Chimica Acta, 1996, 246, 21-38.	0.5	94
116	Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. Cmaj, 2006, 174, 1124-1129.	0.9	94
117	Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol. Journal of Biological Chemistry, 2007, 282, 5207-5216.	1.6	94
118	Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650). Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2450-2455.	1.1	94
119	Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor Î³ Associated With Carotid Atherosclerosis. Stroke, 2004, 35, 2036-2040.	1.0	93
120	Canadian Cardiovascular Society Position Statement onÂFamilial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	0.8	93
121	Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis, 2005, 178, 319-325.	0.4	91
122	Exome Sequencing as a Diagnostic Tool for Pediatricâ€Onset Ataxia. Human Mutation, 2014, 35, 45-49.	1.1	91
123	Targeted next-generation sequencing in monogenic dyslipidemias. Current Opinion in Lipidology, 2015, 26, 103-113.	1.2	91
124	Paraoxonase Genes and Disease. Annals of Medicine, 1999, 31, 217-224.	1.5	90
125	Low incidence of cardiovascular disease among the Inuitâ€"what is the evidence?. Atherosclerosis, 2003, 166, 351-357.	0.4	90
126	Enhanced Synthesis of the Oxysterol 24(S),25-Epoxycholesterol in Macrophages by Inhibitors of 2,3-Oxidosqualene:Lanosterol Cyclase. Circulation Research, 2003, 93, 717-725.	2.0	90

#	Article	IF	Citations
127	Genetics of Triglycerides and the Risk of Atherosclerosis. Current Atherosclerosis Reports, 2017, 19, 31.	2.0	89
128	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Human Molecular Genetics, 2009, 18, 4189-4194.	1.4	88
129	DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. Journal of Human Genetics, 2002, 47, 0620-0622.	1.1	87
130	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2007, 23, 539-550.	0.8	87
131	Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovascular Diabetology, 2008, 7, 5.	2.7	87
132	Temtamy Preaxial Brachydactyly Syndrome Is Caused by Loss-of-Function Mutations in Chondroitin Synthase 1, a Potential Target of BMP Signaling. American Journal of Human Genetics, 2010, 87, 757-767.	2.6	86
133	An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1916-1926.	1.1	84
134	APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis, 2013, 231, 218-222.	0.4	84
135	ClinVar database of global familial hypercholesterolemiaâ€associated DNA variants. Human Mutation, 2018, 39, 1631-1640.	1.1	84
136	Metabolic syndrome in aboriginal Canadians: Prevalence and genetic associations. Atherosclerosis, 2006, 184, 121-129.	0.4	83
137	Hepatic Lipase Deficiency. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 547-572.	2.7	82
138	A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2003, 278, 13442-13452.	1.6	82
139	Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends in Endocrinology and Metabolism, 2003, 14, 371-377.	3.1	79
140	Excess of Rare Variants in Nonâ€“Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia. Circulation: Cardiovascular Genetics, 2012, 5, 66-72.	5.1	79
141	Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. American Journal of Cardiology, 1994, 73, 339-345.	0.7	78
142	An approach to ascertain probands with a non-traditional risk factor for carotid atherosclerosis. Atherosclerosis, 1999, 144, 429-434.	0.4	78
143	Transforming Growth Factor-Î²1 Inhibits Macrophage Cholesteryl Ester Accumulation Induced by Native and Oxidized VLDL Remnants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 2011-2018.	1.1	78
144	LMNA mutation position predicts organ system involvement in laminopathies. Clinical Genetics, 2005, 68, 31-34.	1.0	78

#	Article	IF	Citations
145	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 â€“ therapy. Canadian Journal of Cardiology, 2008, 24, 465-475.	0.8	78
146	Phenotypic heterogeneity of sitosterolemia. Journal of Lipid Research, 2004, 45, 2361-2367.	2.0	76
147	NPC1L1: Evolution From Pharmacological Target to Physiological Sterol Transporter. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2433-2438.	1.1	76
148	NovelLPLmutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Canadian Journal of Physiology and Pharmacology, 2009, 87, 151-160.	0.7	76
149	Paraoxonase-2 Gene (PON2) G148 Variant Associated with Elevated Fasting Plasma Glucose in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3373-3377.	1.8	75
150	Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Human Genetics, 2003, 112, 404-408.	1.8	74
151	Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids in Health and Disease, 2007, 6, 23.	1.2	74
152	Transient Infantile Hypertriglyceridemia, Fatty Liver, and Hepatic Fibrosis Caused by Mutated GPD1, Encoding Glycerol-3-Phosphate Dehydrogenase 1. American Journal of Human Genetics, 2012, 90, 49-60.	2.6	74
153	Monogenic Dyslipidemias: Window on Determinants of Plasma Lipoprotein Metabolism. American Journal of Human Genetics, 2001, 69, 1161-1177.	2.6	73
154	Adipokines and Incident Type 2 Diabetes in an Aboriginal Canadian Population. Diabetes Care, 2008, 31, 1410-1415.	4.3	72
155	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.3	72
156	Common Genomic Variation in the APOC3 Promoter Associated With Variation in Plasma Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2753-2758.	1.1	71
157	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. Journal of Clinical Investigation, 2010, 120, 2889-2899.	3.9	71
158	A Single Nucleotide Polymorphism in Protein Tyrosine Phosphatase PTP-1B Is Associated with Protection from Diabetes or Impaired Glucose Tolerance in Oji-Cree. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 724-727.	1.8	70
159	Advances in Genomic Analysis of Stroke. Stroke, 2010, 41, 825-832.	1.0	70
160	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2020, 14, 398-413.	0.6	70
161	A Single-Base Mutation in the Peroxisome Proliferator-Activated Receptor Î³4 Promoter Associated with Alteredin VitroExpression and Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5655-5660.	1.8	69
162	Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. Journal of Lipid Research, 2005, 46, 366-372.	2.0	69

#	Article	IF	Citations
163	Complications of Type 2 Diabetes Among Aboriginal Canadians: Prevalence and associated risk factors. Diabetes Care, 2005, 28, 2054-2057.	4.3	69
164	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
165	Human C-reactive protein (CRP) 1059G/C polymorphism. Journal of Human Genetics, 2000, 45, 100-101.	1.1	68
166	Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide. Journal of Biological Chemistry, 2015, 290, 25863-25875.	1.6	68
167	Cardiac ryanodine receptor calcium release deficiency syndrome. Science Translational Medicine, 2021, 13, .	5.8	68
168	Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis, 2019, 283, 137-142.	0.4	67
169	G Protein Î²3 Subunit Gene Variant and Blood Pressure Variation in Canadian Oji-Cree. Hypertension, 1998, 32, 688-692.	1.3	66
170	Missense Mutations in APOB within the Î²Î±1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2007, 282, 24270-24283.	1.6	66
171	Copy Number Variation in the Human Genome and Its Implications for Cardiovascular Disease. Circulation, 2007, 115, 3130-3138.	1.6	66
172	Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum. Molecular Genetics and Metabolism, 2008, 93, 282-294.	0.5	66
173	Lipoprotein(a) Is Associated Differentially With Carotid Stenosis, Occlusion, and Total Plaque Area. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1851-1856.	1.1	66
174	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 3620-3630.	1.1	66
175	Peroxisome Proliferator-Activated Receptor-Î³2 P12A and Type 2 Diabetes in Canadian Oji-Cree*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2014-2019.	1.8	65
176	Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia. Journal of Lipid Research, 2017, 58, 2202-2209.	2.0	65
177	Pituitary apoplexy associated with a triple bolus test. Journal of Neurosurgery, 1984, 61, 586-590.	0.9	64
178	Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 111-116.	1.1	64
179	Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clinical Genetics, 2004, 67, 175-177.	1.0	64
180	Combined hyperlipidemia. Current Opinion in Lipidology, 2016, 27, 131-140.	1.2	64

#	Article	IF	Citations
181	Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis, 1998, 139, 131-136.	0.4	62
182	Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?. PLoS Genetics, 2009, 5, e1000694.	1.5	62
183	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	0.8	62
184	Absence of association between genetic variation in the LIPC gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis, 1999, 146, 153-160.	0.4	61
185	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
186	Multiple Genetic Determinants of Variation of Plasma Lipoproteins in Alberta Hutterites. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 861-871.	1.1	61
187	The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Research and Clinical Practice, 2002, 55, 165-173.	1.1	60
188	Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. American Journal of Clinical Nutrition, 2004, 79, 1110-1117.	2.2	60
189	Genetic variation inLMNAmodulates plasma leptin and indices of obesity in aboriginal Canadians. Physiological Genomics, 2000, 3, 39-44.	1.0	59
190	Apolipoprotein C-III. Circulation Research, 2013, 112, 1405-1408.	2.0	59
191	Familial Partial Lipodystrophy: A Monogenic Form of the Insulin Resistance Syndrome. Molecular Genetics and Metabolism, 2000, 71, 539-544.	0.5	58
192	Alstrom syndrome (OMIM 203800): a case report and literature review. Orphanet Journal of Rare Diseases, 2007, 2, 49.	1.2	58
193	A Multiplex Human Syndrome Implicates a Key Role for Intestinal Cell Kinase in Development of Central Nervous, Skeletal, and Endocrine Systems. American Journal of Human Genetics, 2009, 84, 134-147.	2.6	58
194	A Novel LIPE Nonsense Mutation Found Using Exome Sequencing in Siblings With Late-Onset Familial PartialÂLipodystrophy. Canadian Journal of Cardiology, 2014, 30, 1649-1654.	0.8	58
195	Nonstatin Low-Density Lipoproteinâ€“Lowering Therapy and Cardiovascular Risk Reductionâ€”Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2269-2280.	1.1	58
196	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Annual Review of Pharmacology and Toxicology, 2017, 57, 223-244.	4.2	58
197	Common Genomic Variants Associated With Variation in Plasma Lipoproteins in Young Aboriginal Canadians. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1060-1066.	1.1	58
198	Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. , 2000, 15, 294-295.		57

#	Article	IF	Citations
199	Heterogeneity of Nuclear Lamin A Mutations in Dunnigan-Type Familial Partial Lipodystrophy*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3431-3435.	1.8	57
200	Genetics of metabolic syndrome. Current Diabetes Reports, 2008, 8, 141-148.	1.7	57
201	Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. Journal of Lipid Research, 2008, 49, 349-357.	2.0	57
202	Cystathionine Î³-lyase: Clinical, metabolic, genetic, and structural studies. Molecular Genetics and Metabolism, 2009, 97, 250-259.	0.5	57
203	Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. PLoS ONE, 2013, 8, e66808.	1.1	57
204	Complexity of mechanisms among human proprotein convertase subtilisinâ€“kexin type 9 variants. Current Opinion in Lipidology, 2017, 28, 161-169.	1.2	57
205	V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet, The, 1997, 349, 1221-1222.	6.3	56
206	Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis, 2004, 176, 361-370.	0.4	56
207	Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. Journal of Lipid Research, 2009, 50, 1223-1228.	2.0	56
208	Association of Apolipoprotein B with Incident Type 2 Diabetes in an Aboriginal Canadian Population1. Clinical Chemistry, 2010, 56, 666-670.	1.5	56
209	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Canadian Journal of Cardiology, 2018, 34, 595-604.	0.8	56
210	Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility. Genetic Epidemiology, 1987, 4, 163-184.	0.6	55
211	Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. Cmaj, 2009, 180, 617-624.	0.9	55
212	Functional Linkage between the Endoplasmic Reticulum Protein Hsp47 and Procollagen Expression in Human Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2002, 277, 38571-38578.	1.6	54
213	Peroxisomal proliferator activated receptor-Î³ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics, 2006, 7, 3.	2.1	54
214	Validation of Automatically Classified Magnetic Resonance Images for Carotid Plaque Compositional Analysis. Stroke, 2006, 37, 93-97.	1.0	54
215	APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 730-737.	3.3	54
216	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. Journal of Lipid Research, 2009, 50, 1487-1496.	2.0	54

#	Article	IF	Citations
217	Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Medicine, 2009, 1, 28.	3.6	54
218	Geneâ€“diet interactions on plasma lipid levels in the Inuit population. British Journal of Nutrition, 2013, 109, 953-961.	1.2	54
219	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). Journal of Alzheimer's Disease, 2017, 59, 707-721.	1.2	54
220	Targeted next generation sequencing as a tool for precision medicine. BMC Medical Genomics, 2019, 12, 81.	0.7	54
221	Apoa1 related amyloidosis: a case report and literature review. Clinical Biochemistry, 2003, 36, 641-645.	0.8	53
222	Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-Î³. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1606-1612.	1.8	53
223	Exome sequencing identifies <scp>NFS</scp>1 deficiency in a novel Feâ€S cluster disease, infantile mitochondrial complex <scp>II</scp>/<scp>III</scp> deficiency. Molecular Genetics & Genomic Medicine, 2014, 2, 73-80.	0.6	53
224	Statin Intolerance. Circulation, 2015, 131, e389-91.	1.6	53
225	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. Human Molecular Genetics, 2015, 24, 3582-3594.	1.4	53
226	Recent advances in genetic testing for familial hypercholesterolemia. Expert Review of Molecular Diagnostics, 2017, 17, 641-651.	1.5	53
227	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Molecular Pharmaceutics, 2017, 14, 310-318.	2.3	53
228	The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. Genetics in Medicine, 2022, 24, 293-306.	1.1	53
229	Genes, environment and Oji-Cree type 2 diabetes. Clinical Biochemistry, 2003, 36, 163-170.	0.8	52
230	Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease. Lipids in Health and Disease, 2005, 4, 26.	1.2	52
231	Predictors of Mammographic Density: Insights Gained from a Novel Regression Analysis of a Twin Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3474-3481.	1.1	52
232	Six yearsâ€™ experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. BMC Medical Genomics, 2020, 13, 23.	0.7	52
233	Uptake of Type III Hypertriglyceridemic VLDL by Macrophages Is Enhanced by Oxidation, Especially After Remnant Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1707-1715.	1.1	51
234	Polygenic influences on dyslipidemias. Current Opinion in Lipidology, 2018, 29, 133-143.	1.2	51

#	Article	IF	Citations
235	Laminopathies and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1591-1595.	1.1	50
236	Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clinical Genetics, 2004, 65, 483-486.	1.0	50
237	Genetic determinants of carotid ultrasound traits. Current Atherosclerosis Reports, 2006, 8, 206-215.	2.0	50
238	Dyslipidemia. Canadian Journal of Diabetes, 2018, 42, S178-S185.	0.4	50
239	Aortic Xanthomatosis With Coronary Ostial Occlusion in a Child Homozygous for a Nonsense Mutation in ABCG8. Circulation, 2003, 107, 791-791.	1.6	49
240	Lessons from human mutations in PPARÎ³. International Journal of Obesity, 2005, 29, S31-S35.	1.6	49
241	Hypertriglyceridemia: phenomics and genomics. Molecular and Cellular Biochemistry, 2009, 326, 35-43.	1.4	49
242	Polygenic determinants in extremes of high-density lipoprotein cholesterol. Journal of Lipid Research, 2017, 58, 2162-2170.	2.0	49
243	Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. Journal of Lipid Research, 2018, 59, 2421-2435.	2.0	49
244	The evolution of genetic-based risk scores for lipids and cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 71-81.	1.2	49
245	Dyslipidemia Management in Adults With Diabetes. Canadian Journal of Diabetes, 2020, 44, 53-60.	0.4	49
246	Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis, 2001, 159, 231-236.	0.4	48
247	Promoter Polymorphism inPCK1(Phosphoenolpyruvate Carboxykinase Gene) Associated with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 898-903.	1.8	48
248	Extremes of Unexplained Variation as a Phenotype. Circulation: Cardiovascular Genetics, 2010, 3, 215-221.	5.1	48
249	Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of Lipid Research, 2010, 51, 1201-1207.	2.0	48
250	Intellectual disability associated with a homozygous missense mutation in THOC6. Orphanet Journal of Rare Diseases, 2013, 8, 62.	1.2	48
251	The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. Journal of Clinical Lipidology, 2018, 12, 152-161.	0.6	48
252	Successful Outcome in Severe Pregnancy-Associated Hyperlipemia: A Case Report and Literature Review. American Journal of the Medical Sciences, 1995, 309, 213-218.	0.4	47

#	Article	IF	Citations
253	Activation of Peroxisome Proliferator-Activated Receptor Î´ Inhibits Human Macrophage Foam Cell Formation and the Inflammatory Response Induced by Very Low-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2919-2928.	1.1	47
254	Lomitapide for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2017, 18, 1261-1268.	0.9	47
255	A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1005-1014.	1.8	47
256	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	1.5	47
257	Genetic Variation on Chromosome 1 Associated With Variation in Body Fat Distribution in Men. Circulation, 1995, 92, 1089-1093.	1.6	47
258	Beta blockers normalize QT hysteresis in long QT syndrome. American Heart Journal, 2002, 143, 528-534.	1.2	46
259	Human Smooth Muscle Cell Subpopulations Differentially Accumulate Cholesteryl Ester When Exposed to Native and Oxidized Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1290-1296.	1.1	46
260	Genetic and physiological insights into the metabolic syndrome. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R663-R669.	0.9	46
261	Validation of volumetric and singleâ€slice MRI adipose analysis using a novel fully automated segmentation method. Journal of Magnetic Resonance Imaging, 2015, 41, 233-241.	1.9	46
262	The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology, 2015, 31, 605-612.	0.8	46
263	Common Genomic Variation inLMNAModulates Indexes of Obesity in Inuit1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2747-2751.	1.8	45
264	G-Protein Estrogen Receptor as a Regulator of Low-Density Lipoprotein Cholesterol Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 213-221.	1.1	45
265	A truncating mutation in CEP55 is the likely cause of MARCH, a novel syndrome affecting neuronal mitosis. Journal of Medical Genetics, 2017, 54, 490-501.	1.5	45
266	Cholesterol-Lowering Agents. Circulation Research, 2019, 124, 364-385.	2.0	45
267	Insulin's centenary: the birth of an idea. Lancet Diabetes and Endocrinology,the, 2020, 8, 971-977.	5.5	45
268	LMNA R482Q Mutation in Partial Lipodystrophy Associated with Reduced Plasma Leptin Concentration*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3089-3093.	1.8	44
269	The role of genetic testing in dyslipidaemia. Pathology, 2019, 51, 184-192.	0.3	44
270	Human hepatic lipase mutations and polymorphisms. Human Mutation, 1992, 1, 320-324.	1.1	43

#	Article	IF	Citations
271	Allelic and phenotypic spectrum of plasma triglycerides. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 833-842.	1.2	43
272	A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes. Cardiovascular Ultrasound, 2005, 3, 15.	0.5	42
273	ALMNASplicing Mutation in Two Sisters with Severe Dunnigan-Type Familial Partial Lipodystrophy Type 2. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2689-2695.	1.8	42
274	The failure of torcetrapib: what have we learned?. British Journal of Pharmacology, 2008, 154, 1379-1381.	2.7	42
275	Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. Journal of Lipid Research, 2009, 50, 768-772.	2.0	42
276	Phenomics: Expanding the Role of Clinical Evaluation in Genomic Studies. Journal of Investigative Medicine, 2010, 58, 700-706.	0.7	42
277	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2632-2640.	1.1	42
278	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
279	A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Clinical Biochemistry, 1998, 31, 609-612.	0.8	41
280	Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study. American Heart Journal, 2000, 140, 272-278.	1.2	41
281	Lipoprotein Lipase (LPL) Gene Variation and Progression of Carotid Artery Plaque. Stroke, 2003, 34, 1176-1180.	1.0	41
282	Niacin: another look at an underutilized lipid-lowering medication. Nature Reviews Endocrinology, 2012, 8, 517-528.	4.3	41
283	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. PLoS ONE, 2012, 7, e50198.	1.1	40
284	The apolipoprotein E gene and the serum low-density lipoprotein cholesterol response to dietary fiber. Metabolism: Clinical and Experimental, 1993, 42, 585-593.	1.5	39
285	3D Ultrasound Imaging of the Carotid Arteries. Current Drug Targets Cardiovascular & Haematological Disorders, 2004, 4, 161-175.	2.0	39
286	Noninvasive Phenotypes of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, e188; author reply e188-9.	1.1	39
287	Novel mutation inDGUOK in hepatocerebral mitochondrial DNA depletion syndrome associated with cystathioninuria. American Journal of Medical Genetics, Part A, 2005, 135A, 289-291.	0.7	39
288	A novel nonsense apolipoprotein A-I mutation (apoA-IE136X) causes low HDL cholesterol in French Canadians. Atherosclerosis, 2006, 185, 127-136.	0.4	39

#	Article	IF	Citations
289	Association between the -455T>C promoter polymorphism of the APOC3gene and the metabolic syndrome in a multi-ethnic sample. BMC Medical Genetics, 2007, 8, 80.	2.1	39
290	HNF1AG319S variant, active cigarette smoking and incident type 2 diabetes in Aboriginal Canadians: a population-based epidemiological study. BMC Medical Genetics, 2011, 12, 1.	2.1	39
291	Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2020, 76, 2736-2739.	1.2	39
292	Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. Genomics, 2003, 81, 1-5.	1.3	38
293	Blood pressure among the Inuit (Eskimo) populations in the Arctic. Scandinavian Journal of Public Health, 2003, 31, 92-99.	1.2	38
294	The end of the road for CETP inhibitors after torcetrapib?. Current Opinion in Cardiology, 2009, 24, 364-371.	0.8	38
295	Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. Atherosclerosis, 2009, 203, 192-200.	0.4	37
296	Clinical utility gene card for: Abetalipoproteinaemia. European Journal of Human Genetics, 2012, 20, 1-3.	1.4	37
297	A novel ICK mutation causes ciliary disruption and lethal endocrine-cerebro-osteodysplasia syndrome. Cilia, 2016, 5, 8.	1.8	37
298	Molecular basis of partial lipodystrophy and prospects for therapy. Trends in Molecular Medicine, 2001, 7, 121-126.	3.5	36
299	Sex, Diabetes, and Stroke After Carotid Endarterectomy. Diabetes Care, 2003, 26, 1641-1641.	4.3	36
300	Sortilin: An unusual suspect in cholesterol metabolism. BioEssays, 2011, 33, 430-437.	1.2	36
301	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports, 2017, 19, 1456-1466.	2.9	36
302	Identification of a novel synaptic protein, TMTC3, involved in periventricular nodular heterotopia with intellectual disability and epilepsy. Human Molecular Genetics, 2017, 26, 4278-4289.	1.4	36
303	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2020, 13, 515-523.	1.6	36
304	Ketogenic diets, not for everyone. Journal of Clinical Lipidology, 2021, 15, 61-67.	0.6	36
305	HFE S65C Variant Is Not Associated with Increased Transferrin Saturation in Voluntary Blood Donors. Blood Cells, Molecules, and Diseases, 1999, 25, 354-357.	0.6	35
306	Association of Parity With Risk of Type 2 Diabetes and Related Metabolic Disorders. Diabetes Care, 2002, 25, 690-695.	4.3	35

#	Article	IF	Citations
307	Relationship of the metabolic syndrome to carotid ultrasound traits. Cardiovascular Ultrasound, 2006, 4, 28.	0.5	35
308	The Complex Genetic Basis of Plasma Triglycerides. Current Atherosclerosis Reports, 2012, 14, 227-234.	2.0	35
309	A novel MC4R mutation associated with childhood-onset obesity: A case report. Paediatrics and Child Health, 2014, 19, 515-518.	0.3	35
310	A common hypofunctional genetic variant of <scp>GPER</scp> is associated with increased blood pressure in women. British Journal of Clinical Pharmacology, 2014, 78, 1441-1452.	1.1	35
311	Mining the genome for lipid genes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1993-2009.	1.8	35
312	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	1.2	35
313	HDL re-examined. Current Opinion in Lipidology, 2015, 26, 127-132.	1.2	35
314	A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1454-1457.	1.8	35
315	Compound heterozygosity for mutant hepatic lipase in familial hepatic lipase deficiency. Biochemical and Biophysical Research Communications, 1991, 179, 78-84.	1.0	34
316	Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics and Genomics, 1999, 9, 351-356.	5.7	34
317	Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1316-1324.	0.8	34
318	What Is Familial Hypercholesterolemia, and Why Does It Matter?. Circulation, 2020, 141, 1760-1763.	1.6	34
319	Angiotensinogen Gene Variation Associated With Variation in Blood Pressure in Aboriginal Canadians. Hypertension, 1997, 29, 1073-1077.	1.3	34
320	Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase. Clinical Biochemistry, 2002, 35, 125-130.	0.8	33
321	Phenomics, Lipodystrophy, and the Metabolic Syndrome. Trends in Cardiovascular Medicine, 2004, 14, 133-137.	2.3	33
322	Genetics of metabolic syndrome: Is there a role for phenomics?. Current Atherosclerosis Reports, 2008, 10, 201-208.	2.0	33
323	Role of DNA copy number variation in dyslipidemias. Current Opinion in Lipidology, 2018, 29, 125-132.	1.2	33
324	Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene. Genetic Epidemiology, 1990, 7, 69-81.	0.6	32

#	Article	IF	Citations
325	Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. Human Mutation, 2001, 18, 359-359.	1.1	32
326	Free Fatty Acid-Mediated Impairment of Glucose-Stimulated Insulin Secretion in Nondiabetic Oji-Cree Individuals From the Sandy Lake Community of Ontario, Canada: A Population at Very High Risk for Developing Type 2 Diabetes. Diabetes, 2003, 52, 1485-1495.	0.3	32
327	Peroxisome proliferator-activated receptor Î³ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2007, 21, 166-171.	1.2	32
328	Multi-Ethnic Genetic Association Study of Carotid Intima-Media Thickness Using a Targeted Cardiovascular SNP Microarray. Stroke, 2009, 40, 3173-3179.	1.0	32
329	Matching Two Independent Cohorts ValidatesDPH1as a Gene Responsible for Autosomal Recessive Intellectual Disability with Short Stature, Craniofacial, and Ectodermal Anomalies. Human Mutation, 2015, 36, 1015-1019.	1.1	32
330	Loss-of-Function Mutations inABCA1and Enhanced Î²-Cell Secretory Capacity in Young Adults. Diabetes, 2015, 64, 193-199.	0.3	32
331	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. Journal of Lipid Research, 2017, 58, 2188-2196.	2.0	32
332	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 2019, 3, 2397-2410.	0.1	32
333	The polygenic nature of mild-to-moderate hypertriglyceridemia. Journal of Clinical Lipidology, 2020, 14, 28-34.e2.	0.6	32
334	Lipoprotein(a) and coronary heart disease risk. Current Cardiology Reports, 1999, 1, 105-111.	1.3	31
335	Non-Invasive Assessment of Atherosclerosis Risk. Current Drug Targets Cardiovascular & Haematological Disorders, 2004, 4, 125-128.	2.0	31
336	Genetics 100 for Cardiologists: Basics of Genome-Wide Association Studies. Canadian Journal of Cardiology, 2013, 29, 10-17.	0.8	31
337	Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 444-451.	1.1	31
338	Congenital sucraseâ€“isomaltase deficiency: identification of a common Inuit founder mutation. Cmaj, 2015, 187, 102-107.	0.9	31
339	The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. Journal of Clinical Investigation, 2003, 111, 1118-1120.	3.9	31
340	Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations. Atherosclerosis, 2001, 154, 579-587.	0.4	30
341	Optimizing RNA extraction yield from whole blood for microarray gene expression analysis. Clinical Biochemistry, 2004, 37, 741-744.	0.8	30
342	Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Medical Imaging, 2006, 6, 11.	1.4	30

#	Article	IF	Citations
343	A homozygousPMS2founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. Journal of Medical Genetics, 2015, 52, 348-352.	1.5	30
344	Sanfilippo Syndrome Type D. Archives of Neurology, 2007, 64, 1629.	4.9	29
345	Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. Journal of Clinical Lipidology, 2019, 13, 89-99.	0.6	29
346	Tangier disease: update for 2020. Current Opinion in Lipidology, 2020, 31, 80-84.	1.2	29
347	Modification of Type III VLDL, Their Remnants, and VLDL From ApoE-Knockout Mice by p -Hydroxyphenylacetaldehyde, a Product of Myeloperoxidase Activity, Causes Marked Cholesteryl Ester Accumulation in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1238-1249.	1.1	28
348	Single nucleotide polymorphisms of the resistin (RSTN) gene. Journal of Human Genetics, 2001, 46, 553-555.	1.1	28
349	Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Cardiovascular Diabetology, 2005, 4, 17.	2.7	28
350	Cockayne syndrome type A: novel mutations in eight typical patients. Journal of Human Genetics, 2006, 51, 701-705.	1.1	28
351	Comparison of Gadofluorine-M and Gd-DTPA for Noninvasive Staging of Atherosclerotic Plaque Stability Using MRI. Circulation: Cardiovascular Imaging, 2009, 2, 226-234.	1.3	28
352	Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. Human Molecular Genetics, 2014, 23, 2498-2510.	1.4	28
353	Old gene, new phenotype: mutations in heparan sulfate synthesis enzyme, EXT2 leads to seizure and developmental disorder, no exostoses. Journal of Medical Genetics, 2015, 52, 666-675.	1.5	28
354	Apolipoprotein A-I Deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 2157-2164.	1.1	27
355	Variation in the AU(AT)-Rich Element within the 3â€²-Untranslated Region ofPPP1R3Is Associated with Variation in Plasma Glucose in Aboriginal Canadians¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3980-3983.	1.8	27
356	DNA polymorphism and mutations in CPN1, including the genomic basis of carboxypeptidase N deficiency. Journal of Human Genetics, 2003, 48, 0020-0022.	1.1	27
357	Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Human Molecular Genetics, 2003, 12, 1131-1143.	1.4	27
358	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Canadian Journal of Cardiology, 2014, 30, 377-380.	0.8	27
359	Cholesterol Lowering and Prevention of Stroke. Stroke, 2019, 50, 537-541.	1.0	27
360	A glimpse at HDL-based therapy for atherosclerosis. Clinical Biochemist Reviews, 2004, 25, 3-5.	3.3	27

#	Article	IF	Citations
361	Association between PON1 L/M55 Polymorphism and Plasma Lipoproteins in Two Canadian Aboriginal Populations. Clinical Chemistry and Laboratory Medicine, 2000, 38, 413-20.	1.4	26
362	Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 77-83.	1.8	26
363	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. Journal of Lipid Research, 2003, 44, 1508-1514.	2.0	26
364	Pituitary Growth Hormone and Growth Hormone-Releasing Hormone Receptor Genes and Associations with Mammographic Measures and Serum Growth Hormone. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2648-2654.	1.1	26
365	A frameshift mutation in peroxisome-proliferator-activated receptor-Î³ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clinical Genetics, 2006, 70, 360-362.	1.0	26
366	Evaluation of adipose tissue volume quantification with IDEAL fatâ€“water separation. Journal of Magnetic Resonance Imaging, 2011, 34, 474-479.	1.9	26
367	HDLâ€”is it too big to fail?. Nature Reviews Endocrinology, 2013, 9, 308-312.	4.3	26
368	Linkage analysis and exome sequencing identify a novel mutation in <scp>KCTD</scp>7 in patients with progressive myoclonus epilepsy with ataxia. Epilepsia, 2014, 55, e106-11.	2.6	26
369	Pharmacogenomics, Lipid Disorders, and Treatment Options. Clinical Pharmacology and Therapeutics, 2014, 96, 36-47.	2.3	26
370	The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. Npj Genomic Medicine, 2016, 1, 16032.	1.7	26
371	Complex effects of laminopathy mutations on nuclear structure and function. Clinical Genetics, 2019, 95, 199-209.	1.0	26
372	Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of Highâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2018, 7, e009545.	1.6	25
373	Genetics of hypertriglyceridemia and atherosclerosis. Current Opinion in Cardiology, 2021, 36, 264-271.	0.8	25
374	Constructing Treatment Portfolios Using Affinity Propagation. Lecture Notes in Computer Science, 2008, , 360-371.	1.0	25
375	Drawing the line in progeria syndromes. Lancet, The, 2003, 362, 416-417.	6.3	24
376	CKN1 (MIM 216400): mutations in Cockayne syndrome type A and a new common polymorphism. Journal of Human Genetics, 2004, 49, 61-63.	1.1	24
377	Disparate Associations of a Functional Promoter Polymorphism in PCK1 With Carotid Wall Ultrasound Traits. Stroke, 2005, 36, 2566-2570.	1.0	24
378	Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Medical Imaging, 2007, 7, 3.	1.4	24

#	Article	IF	Citations
379	Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. Journal of Lipid Research, 2009, 50, 1216-1222.	2.0	24
380	Using Mendelian randomization to determine causative factors in cardiovascular disease. Journal of Internal Medicine, 2013, 273, 44-47.	2.7	24
381	Mannose-binding Lectin Gene Variation and Cardiovascular Disease in Canadian Inuit. Clinical Chemistry, 1999, 45, 1283-1285.	1.5	23
382	The envelope, please: Nuclear lamins and disease. Nature Medicine, 2000, 6, 136-137.	15.2	23
383	Genetic variation in paraoxonaseâ€2 is associated with variation in plasma lipoproteins in Canadian Ojiâ€Cree. Clinical Genetics, 1998, 54, 394-399.	1.0	23
384	The Oxysterol 24 (S) ,25â€Epoxycholesterol Attenuates Human Smooth Muscleâ€“Derived Foam Cell Formation Via Reduced Lowâ€Density Lipoprotein Uptake and Enhanced Cholesterol Efflux. Journal of the American Heart Association, 2012, 1, e000810.	1.6	23
385	Homozygous Lamin A/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy. Neuromuscular Disorders, 2013, 23, 265-268.	0.3	23
386	CETP Inhibitors â€" A New Inning?. New England Journal of Medicine, 2017, 377, 1284-1285.	13.9	23
387	Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). American Journal of Cardiology, 2019, 124, 1876-1880.	0.7	23
388	Genetic prediction of atherosclerosis: lessons from studies in native Canadian populations. Clinica Chimica Acta, 1999, 286, 47-61.	0.5	22
389	The Private Hepatocyte Nuclear Factor-1Î± G319S Variant Is Associated With Plasma Lipoprotein Variation in Canadian Oji-Cree. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 217-222.	1.1	22
390	The molecular basis of genetic lipodystrophies. Clinical Biochemistry, 2002, 35, 171-177.	0.8	22
391	Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus. Journal of Biological Chemistry, 2003, 278, 11985-11994.	1.6	22
392	Western Database of Lipid Variants (WDLV): A Catalogue of Genetic Variants in Monogenic Dyslipidemias. Canadian Journal of Cardiology, 2013, 29, 934-939.	0.8	22
393	Familial partial lipodystrophy presenting as metabolic syndrome. Journal of Clinical Lipidology, 2016, 10, 1488-1491.	0.6	22
394	Unusual genetic variants associated with hypercholesterolemia in Argentina. Atherosclerosis, 2018, 277, 256-261.	0.4	22
395	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. Journal of Lipid Research, 2018, 59, 1529-1535.	2.0	22
396	A Common mtDNA Polymorphism Associated with Variation in Plasma Triglyceride Concentration. American Journal of Human Genetics, 1997, 60, 1552-1555.	2.6	21

#	Article	IF	Citations
397	Environmental modulation of atherosclerosis end points in familial hypercholesterolemia. Atherosclerosis Supplements, 2002, 2, 5-7.	1.2	21
398	Identification of single-nucleotide polymorphisms in the human LPIN1 gene. Journal of Human Genetics, 2002, 47, 370-372.	1.1	21
399	Phenomics and lamins: From disease to therapy. Experimental Cell Research, 2007, 313, 2134-2143.	1.2	21
400	Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Human Molecular Genetics, 2014, 23, 5570-5578.	1.4	21
401	Estrogen-associated severe hypertriglyceridemia with pancreatitis. Journal of Clinical Lipidology, 2017, 11, 297-300.	0.6	21
402	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.4	21
403	Genetic and Biochemical Factors Associated With Variation in Blood Pressure in a Genetic Isolate. Hypertension, 1996, 27, 308-312.	1.3	21
404	Phenomics: expanding the role of clinical evaluation in genomic studies. Journal of Investigative Medicine, 2010, 58, 700-6.	0.7	21
405	Prevalence of Reproductive Abnormalities Among Women with Familial Partial Lipodystrophy. Endocrine Practice, 2008, 14, 1126-1132.	1.1	21
406	Genomic copy number variation and its potential role in lipoprotein and metabolic phenotypes. Current Opinion in Lipidology, 2007, 18, 174-180.	1.2	20
407	Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. Journal of Lipid Research, 2016, 57, 1601-1607.	2.0	20
408	Lomitapide for the treatment of hypertriglyceridemia. Expert Opinion on Investigational Drugs, 2016, 25, 1457-1463.	1.9	20
409	Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?. Current Atherosclerosis Reports, 2016, 18, 24.	2.0	20
410	Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia. Journal of Clinical Lipidology, 2021, 15, 79-87.	0.6	20
411	Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-Î³. Journal of Lipid Research, 1999, 40, 1017-1028.	2.0	20
412	Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 1361-1368.	0.8	20
413	Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. American Journal of Cardiology, 1989, 63, 109-112.	0.7	19
414	Human aryl hydrocarbon receptor nuclear translocator gene (ARNT) D/N511 polymorphism. Journal of Human Genetics, 2000, 45, 92-93.	1.1	19

#	Article	IF	Citations
415	Genes and environment in type 2 diabetes and atherosclerosis in aboriginal canadians. Current Atherosclerosis Reports, 2001, 3, 216-221.	2.0	19
416	GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY). Human Mutation, 2002, 20, 478-479.	1.1	19
417	Genetic susceptibility to heart disease in Canada: lessons from patients with familial hypercholesterolemia. Genome, 2006, 49, 1343-1350.	0.9	19
418	Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome. Endocrine Practice, 2007, 13, 656-661.	1.1	19
419	Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population. Nutrition and Metabolism, 2013, 10, 26.	1.3	19
420	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opinion on Investigational Drugs, 2013, 22, 1411-1423.	1.9	19
421	Targeted sequencing reveals expanded genetic diversity of human transfer RNAs. RNA Biology, 2019, 16, 1574-1585.	1.5	19
422	Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice. Lancet Diabetes and Endocrinology,the, 2019, 7, 880-886.	5.5	19
423	Loss-of-FunctionCREB3L3Variants in Patients With Severe Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1935-1941.	1.1	19
424	Retinopathy and Neuropathy Associated With Complete Apolipoprotein A-I Deficiency. American Journal of the Medical Sciences, 1996, 312, 30-33.	0.4	19
425	Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thrombosis and Haemostasis, 2003, 90, 1187-1191.	1.8	18
426	Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrology Dialysis Transplantation, 2007, 22, 2084-2088.	0.4	18
427	Inherited lipodystrophies and the metabolic syndrome. Clinical Endocrinology, 2007, 67, 070611020455003-???.	1.2	18
428	Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2010, 11, 2569-2572.	0.9	18
429	Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARÎ³ deficiency. Journal of Lipid Research, 2012, 53, 1968-1978.	2.0	18
430	Polygenic Risk for Hypertriglyceridemia Can Mimic a Major Monogenic Mutation. Annals of Internal Medicine, 2017, 167, 360.	2.0	18
431	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.4	18
432	Progress in finding pathogenic DNA copy number variations in dyslipidemia. Current Opinion in Lipidology, 2019, 30, 63-70.	1.2	18

#	Article	IF	Citations
433	Parkinson's Disease, <scp>NOTCH3</scp> Genetic Variants, and White Matter Hyperintensities. Movement Disorders, 2020, 35, 2090-2095.	2.2	18
434	Identification of polymorphisms in the human SHP1 gene. Journal of Human Genetics, 2002, 47, 445-447.	1.1	17
435	Assembly and Secretion of Very Low Density Lipoproteins Containing Apolipoprotein B48 in Transfected McA-RH7777 Cells. Journal of Biological Chemistry, 2003, 278, 14153-14161.	1.6	17
436	Complex Trait Locus Linkage Mapping in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1541-1544.	1.1	17
437	Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. International Journal of Circumpolar Health, 2007, 66, 390-400.	0.5	17
438	Increased Blood Pressure and Hyperdynamic Cardiovascular Responses in Carriers of a Common Hyperfunctional Variant of Adenylyl Cyclase 6. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 451-457.	1.3	17
439	Exome Sequencing: New Insights into Lipoprotein Disorders. Current Cardiology Reports, 2014, 16, 507.	1.3	17
440	Genetic Confirmation Rate in Clinically Suspected Maturity-Onset Diabetes of the Young. Canadian Journal of Diabetes, 2016, 40, 555-560.	0.4	17
441	Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease. Journal of Visualized Experiments, 2018, , .	0.2	17
442	Whole genome sequencing in the clinic: empowerment or too much information?. Cmaj, 2018, 190, E124-E125.	0.9	17
443	A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States. Clinical Therapeutics, 2019, 41, 426-444.	1.1	17
444	Apolipoprotein B and E Basic Amino Acid Clusters Influence Low-Density Lipoprotein Association with Lipoprotein Lipase Anchored to the Subendothelial Matrix. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1240-1247.	1.1	17
445	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	3.9	17
446	Statin Safety in Chinese: A Population-Based Study of Older Adults. PLoS ONE, 2016, 11, e0150990.	1.1	17
447	Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet, The, 1997, 350, 785.	6.3	16
448	Variation of Candidate Genes in Triglyceride Metabolism. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 309-315.	3.1	16
449	A BRCA1 mutation in Native North American families. Human Mutation, 2002, 19, 460-460.	1.1	16
450	Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia. Cmaj, 2005, 172, 495-497.	0.9	16

#	Article	IF	Citations
451	Variation in Niemannâ€“Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clinical Endocrinology, 2008, 69, 45-51.	1.2	16
452	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain, 2009, 132, 1346-1354.	3.7	16
453	HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. Journal of Clinical Lipidology, 2013, 7, 169-173.	0.6	16
454	Whole-genome sequencing in French Canadians from Quebec. Human Genetics, 2016, 135, 1213-1221.	1.8	16
455	Low LDL cholesterolâ€”Friend or foe?. Journal of Clinical Lipidology, 2019, 13, 367-373.	0.6	16
456	2019 George Lyman Duff Memorial Lecture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1970-1981.	1.1	16
457	Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 685-693.	0.6	16
458	Pediatric Dyslipidemiaâ€”Beyond Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2020, 36, 1362-1371.	0.8	16
459	Genetic determinants of plasma lipoproteins. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 600-609.	3.3	15
460	Update on the Genetics of Stroke and Cerebrovascular Disease 2006. Stroke, 2007, 38, 216-218.	1.0	15
461	Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: Resolved and unresolved issues. Canadian Journal of Cardiology, 2008, 24, 293-300.	0.8	15
462	Microsomal triglyceride transfer protein inhibitionâ€“friend or foe?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 506-508.	3.3	15
463	Predicting abdominal adipose tissue among women with familial partial lipodystrophy. Metabolism: Clinical and Experimental, 2009, 58, 828-834.	1.5	15
464	Dyslipidemia. Canadian Journal of Diabetes, 2013, 37, S110-S116.	0.4	15
465	Ezetimibe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e13-5.	1.1	15
466	Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2015, 16, 1255-1262.	0.9	15
467	KMT2D p.Gln3575His segregating in a family with autosomal dominant choanal atresia strengthens the Kabuki/CHARGE connection. American Journal of Medical Genetics, Part A, 2017, 173, 183-189.	0.7	15
468	Cannabis effects on lipoproteins. Current Opinion in Lipidology, 2019, 30, 140-146.	1.2	15

#	Article	IF	Citations
469	GPIHBP1 autoantibody syndrome during interferon Î²1a treatment. Journal of Clinical Lipidology, 2019, 13, 62-69.	0.6	15
470	Enrichment of loss-of-function and copy number variants in ventricular cardiomyopathy genes in â€˜loneâ€™ atrial fibrillation. Europace, 2021, 23, 844-850.	0.7	15
471	NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. Pharmacogenetics and Genomics, 2000, 10, 233-238.	5.7	15
472	Genetic Variation in Factor VII Associated with Variation in Plasma Lipoprotein(a) Concentration. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1701-1706.	1.1	15
473	Familial combined hyperlipidemia is a polygenic trait. Current Opinion in Lipidology, 2022, 33, 126-132.	1.2	15
474	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. Alzheimer's and Dementia, 2023, 19, 226-243.	0.4	15
475	Safety and efficacy of therapies for chylomicronemia. Expert Review of Clinical Pharmacology, 2022, 15, 395-405.	1.3	15
476	Rapid Development of Massive Tendon Xanthomas following Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 2002, 137, 624.	2.0	14
477	Lamin mutations come of age. Nature Medicine, 2003, 9, 644-645.	15.2	14
478	Emerging antidyslipidemic drugs. Expert Opinion on Emerging Drugs, 2008, 13, 363-381.	1.0	14
479	Predictive genetic testing for coronary artery disease. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 343-360.	2.7	14
480	A Translational View of the Genetics of Lipodystrophy and Ectopic Fat Deposition. Progress in Molecular Biology and Translational Science, 2010, 94, 159-196.	0.9	14
481	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). European Journal of Human Genetics, 2012, 20, 3-3.	1.4	14
482	A shared founder mutation underlies restrictive dermopathy in Old Colony (Dutchâ€Œerman) Mennonite and Hutterite patients in North America. American Journal of Medical Genetics, Part A, 2012, 158A, 1229-1232.	0.7	14
483	Common Low-Density Lipoprotein Receptor p.G116S Variant Has a Large Effect on Plasma Low-Density Lipoprotein Cholesterol in Circumpolar Inuit Populations. Circulation: Cardiovascular Genetics, 2015, 8, 100-105.	5.1	14
484	Clinical utility gene card for: Sitosterolaemia. European Journal of Human Genetics, 2017, 25, 512-512.	1.4	14
485	Complex genetic architecture in severe hypobetalipoproteinemia. Lipids in Health and Disease, 2018, 17, 48.	1.2	14
486	Update on the diagnosis, treatment and management of rare genetic lipid disorders. Pathology, 2019, 51, 193-201.	0.3	14

#	Article	IF	Citations
487	Contribution of rare variant associations to neurodegenerative disease presentation. Npj Genomic Medicine, 2021, 6, 80.	1.7	14
488	Effectiveness of a Novel Ï‰-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. JAMA Network Open, 2022, 5, e2141898.	2.8	14
489	Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clinical Biochemistry, 1999, 32, 143-148.	0.8	13
490	Apolipoprotein E Polymorphism and Response to Electroconvulsive Therapy. Journal of ECT, 2001, 17, 11-14.	0.3	13
491	Ankyrin G overexpression in Hutchinson-Gilford progeria syndrome fibroblasts identified through biological filtering of expression profiles. Journal of Human Genetics, 2006, 51, 934-942.	1.1	13
492	APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians. Journal of Lipid Research, 2010, 51, 843-848.	2.0	13
493	Complete Apo AI Deficiency in an Iraqi Mandaean Family: Case studies and review of the literature. Journal of Clinical Lipidology, 2010, 4, 420-426.	0.6	13
494	BRCA2 Variants and cardiovascular disease in a multi-ethnic study. BMC Medical Genetics, 2012, 13, 56.	2.1	13
495	Partial lipodystrophy associated with muscular dystrophy of unknown genetic origin. Muscle and Nerve, 2014, 49, 928-930.	1.0	13
496	Reporting Sex and Sex Differences in Preclinical Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e171-e184.	1.1	13
497	Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. Journal of Clinical Lipidology, 2020, 14, 197-200.	0.6	13
498	Lipid effects of glucagon-like peptide 1 receptor analogs. Current Opinion in Lipidology, 2021, 32, 191-199.	1.2	13
499	Incidence, predictors and patterns of care of patients with very severe hypertriglyceridemia in Ontario, Canada: a population-based cohort study. Lipids in Health and Disease, 2021, 20, 98.	1.2	13
500	Small genetic effects in complex diseases: A review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clinical Biochemistry, 1997, 30, 183-188.	0.8	12
501	Insulin resistance in human partial lipodystrophy. Current Atherosclerosis Reports, 2000, 2, 397-404.	2.0	12
502	Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions. Thrombosis Research, 2004, 114, 137-141.	0.8	12
503	MRI of earlyâ€•and lateâ€stage arterial remodeling in a lowâ€level cholesterolâ€fed rabbit model of atherosclerosis. Journal of Magnetic Resonance Imaging, 2007, 26, 1010-1019.	1.9	12
504	Uncloaking the Genetic Determinants of Metabolic Syndrome. Journal of Nutrigenetics and Nutrigenomics, 2008, 1, 118-125.	1.8	12

#	Article	IF	Citations
505	Genetics 101 for Cardiologists: Rare Genetic Variants and Monogenic Cardiovascular Disease. Canadian Journal of Cardiology, 2013, 29, 18-22.	0.8	12
506	Complying With the National Institutes of Health Guidelines and Principles for Rigor and Reproducibility. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1303-1304.	1.1	12
507	OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 75-85.	1.1	12
508	Multiple Symmetric Lipomatosis (Madelung Disease) in a Large Canadian Family With the Mitochondrial MTTK c.8344A>G Variant. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961880286.	0.3	12
509	Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia. Journal of Lipid Research, 2019, 60, 1953-1958.	2.0	12
510	CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins. Journal of Clinical Investigation, 2021, 131, .	3.9	12
511	Genes, Environment and Diabetes in Canadian Aboriginal Communities. Advances in Experimental Medicine and Biology, 2001, 498, 11-20.	0.8	12
512	Elevated LDL Triglyceride Concentrations in Subjects Heterozygous for the Hepatic Lipase S267F Variant. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1212-1216.	1.1	11
513	Hemochromatosis and Diabetes Mellitus. Annals of Internal Medicine, 1998, 129, 587.	2.0	11
514	Lipoprotein-genotype associations in Trinidadian neonates. Clinical Biochemistry, 1999, 32, 429-437.	0.8	11
515	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. Journal of Human Genetics, 1999, 44, 225-229.	1.1	11
516	DNA polymorphisms of lipase related genes. Journal of Human Genetics, 2003, 48, 443-446.	1.1	11
517	Quality assessment of microarray experiments. Clinical Biochemistry, 2005, 38, 639-642.	0.8	11
518	Increased Enzyme Activity and Î²-Adrenergicâ€“Mediated Vasodilation in Subjects Expressing a Single-Nucleotide Variant of Human Adenylyl Cyclase 6. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2657-2663.	1.1	11
519	Genetic testing for atherosclerosis risk: Inevitability or pipe dream?. Canadian Journal of Cardiology, 2008, 24, 851-854.	0.8	11
520	Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Design, Development and Therapy, 2012, 6, 251.	2.0	11
521	Simple genetics language as source of miscommunication between genetics researchers and potential research participants in informed consent documents. Public Understanding of Science, 2015, 24, 751-766.	1.6	11
522	Rare Genetic Variants and High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, e53-5.	1.1	11

#	Article	IF	Citations
523	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. Atherosclerosis, 2016, 250, 63-68.	0.4	11
524	A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia. Journal of Clinical Lipidology, 2016, 10, 1030-1034.	0.6	11
525	Genetic and epigenetic study of an Alzheimerâ€™s disease family with monozygotic triplets. Brain, 2019, 142, 3375-3381.	3.7	11
526	Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2. Journal of Clinical Lipidology, 2021, 15, 653-657.	0.6	11
527	Elevated plasma lipoprotein(a) associated with abnormal stress thallium scans in children with familial hypercholesterolemia. American Journal of Cardiology, 1993, 72, 402-406.	0.7	10
528	Genetic Variation Associated with Differences in the Response of Plasma Apolipoprotein B Levels to Dietary Fibre. Clinical Science, 1993, 85, 269-275.	1.8	10
529	G-protein polymorphisms and maternal/neonatal metabolism: still a weight for the answer. Lancet, The, 2000, 355, 1201-1202.	6.3	10
530	Biophysical characteristics of a new mutation on the KCNQ1 potassium channel (L251P) causing long QT syndrome. Canadian Journal of Physiology and Pharmacology, 2003, 81, 129-134.	0.7	10
531	Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction1. Transplantation, 2003, 75, 209-216.	0.5	10
532	Retinoid X Receptor Heterodimers in the Metabolic Syndrome. New England Journal of Medicine, 2005, 353, 2088-2088.	13.9	10
533	Obstructive sleep apnea in 2 women with familial partial lipodystrophy due to a heterozygous LMNA R482Q mutation. Cmaj, 2007, 177, 743-745.	0.9	10
534	Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1224-1227.	1.1	10
535	Copy-Number Variations and Human Disease. American Journal of Human Genetics, 2007, 81, 414-415.	2.6	10
536	Transcriptional Profiling of Endocrine Cerebro-Osteodysplasia Using Microarray and Next-Generation Sequencing. PLoS ONE, 2011, 6, e25400.	1.1	10
537	Linking Diabetes With Oxidative Stress, Adipokines, and Impaired Endothelial Precursor Cell Function. Canadian Journal of Cardiology, 2012, 28, 629-630.	0.8	10
538	Clinical Equivalence of Proprietary and Generic Atorvastatin in Lipid Clinic Patients. Canadian Journal of Cardiology, 2013, 29, 418-422.	0.8	10
539	Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin. Canadian Journal of Cardiology, 2013, 29, 915-919.	0.8	10
540	Genetic Determinants of â€œCognitive Impairment, No Dementiaâ€• Journal of Alzheimer's Disease, 2013, 33, 831-840.	1.2	10

#	Article	IF	Citations
541	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB) â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	1.4	10
542	A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome. Journal of Clinical Lipidology, 2018, 12, 506-510.	0.6	10
543	A De Novo POLD1 Mutation Associated With Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome in a Family With Werner Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961878677.	0.3	10
544	Copy Number Variation in GCK in Patients With Maturity-Onset Diabetes of the Young. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3428-3436.	1.8	10
545	Genetic Determinants of Myocardial Infarction Risk in Familial Hypercholesterolemia. CJC Open, 2019, 1, 225-230.	0.7	10
546	Delisting STAP1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 847-849.	1.1	10
547	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. Circulation Genomic and Precision Medicine, 2021, 14, e003182.	1.6	10
548	Unbuckling lipodystrophy from insulin resistance and hypertension. Journal of Clinical Investigation, 2004, 114, 163-165.	3.9	10
549	Evidence for gene-diet interaction in the response of blood pressure to dietary fibre. Nutrition Research, 1997, 17, 1229-1238.	1.3	9
550	Serum C-Reactive Protein in Canadian Inuit and Its Association with Genetic Variation on Chromosome 1q21. Clinical Chemistry, 2001, 47, 1707-1709.	1.5	9
551	Lecithin:cholesterol acyl transferase G30S: association with atherosclerosis, hypoalphalipoproteinemia and reduced in vivo enzyme activity. Clinical Biochemistry, 2001, 34, 381-386.	0.8	9
552	An Unusual Case of Severe Hypertriglyceridemia and Splenomegaly. Clinical Chemistry, 2008, 54, 606-610.	1.5	9
553	Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration. Blood, 2010, 116, 2160-2163.	0.6	9
554	Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study. Cardiovascular Diabetology, 2010, 9, 39.	2.7	9
555	Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis. Case Reports in Gastroenterology, 2012, 6, 429-437.	0.3	9
556	Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene. Lipids in Health and Disease, 2015, 14, 102.	1.2	9
557	The Genetics of Cardiovascular Disease in Canadian and International Aboriginal Populations. Canadian Journal of Cardiology, 2015, 31, 1094-1115.	0.8	9
558	Barriers to the Implementation of Lipoprotein Apheresis in Canada. Canadian Journal of Cardiology, 2017, 33, 409-411.	0.8	9

#	Article	IF	Citations
559	Food Effect on Rosuvastatin Disposition and Lowâ€Density Lipoprotein Cholesterol. Clinical Pharmacology and Therapeutics, 2018, 104, 525-533.	2.3	9
560	Editorial. Current Opinion in Lipidology, 2019, 30, 53-55.	1.2	9
561	Can genetic testing help in the management of dyslipidaemias?. Current Opinion in Lipidology, 2020, 31, 187-193.	1.2	9
562	Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?. European Heart Journal, 2022, 43, 1413-1415.	1.0	9
563	The Impact of Blunted Î²-Adrenergic Responsiveness on Growth Regulatory Pathways in Hypertension. Molecular Pharmacology, 2006, 69, 317-327.	1.0	8
564	Advances in Stroke 2009. Stroke, 2010, 41, e63-6.	1.0	8
565	A mutation in the serine protease TMPRSS4 in a novel pediatric neurodegenerative disorder. Orphanet Journal of Rare Diseases, 2013, 8, 126.	1.2	8
566	Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes, 2015, 39, S183-S190.	0.4	8
567	Clinical utility gene card for: Abetalipoproteinaemia â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	1.4	8
568	New oral agents for treating dyslipidemia. Current Opinion in Lipidology, 2016, 27, 579-584.	1.2	8
569	Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology, 2017, 33, 334-342.	0.8	8
570	Genetic polymorphisms are associated with exposure biomarkers for metals and persistent organic pollutants among Inuit from the Inuvialuit Settlement Region, Canada. Science of the Total Environment, 2018, 634, 569-578.	3.9	8
571	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. Lipids in Health and Disease, 2018, 17, 8.	1.2	8
572	Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia. CJC Open, 2019, 1, 115-118.	0.7	8
573	Annual Report on Sex in Preclinical Studies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e1-e9.	1.1	8
574	Human variant of scavenger receptor BI (R174C) exhibits impaired cholesterol transport functions. Journal of Lipid Research, 2021, 62, 100045.	2.0	8
575	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. Journal of Clinical Lipidology, 2021, 15, 275-291.	0.6	8
576	Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen. Frontiers in Medicine, 2021, 8, 694668.	1.2	8

#	Article	IF	Citations
577	Variation in biomarker levels of metals, persistent organic pollutants, and omega-3 fatty acids in association with genetic polymorphisms among Inuit in Nunavik, Canada. Environmental Research, 2021, 200, 111393.	3.7	8
578	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. Neurobiology of Aging, 2021, 105, 378.e1-378.e9.	1.5	8
579	Cross-Sectional and Prospective Associations between Abdominal Adiposity and Proinsulin Concentration. , 0, .		8
580	ABC Transporters and Sterol Absorption. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 31-37.	2.0	8
581	Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?. Current Atherosclerosis Reports, 2022, 24, 419-426.	2.0	8
582	Hypertriglyceridemia in young adults with a 22q11.2 microdeletion. European Journal of Endocrinology, 2022, 187, 91-99.	1.9	8
583	Restriction isotyping of the premature termination variant of lipoprotein lipase in alberta hutterites. Clinical Biochemistry, 1996, 29, 63-66.	0.8	7
584	Association between AGT T235 variant and microalbuminuria in Canadian Oji-cree with type 2 diabetes mellitus. Clinical Biochemistry, 1999, 32, 201-205.	0.8	7
585	A novel mutation in KVLQT1 , L122P, found in a family with autosomal dominant long QT syndrome. American Heart Journal, 2000, 140, 146-149.	1.2	7
586	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. Journal of Lipid Research, 2013, 54, 1980-1987.	2.0	7
587	Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia â^—. Journal of the American College of Cardiology, 2016, 67, 1286-1288.	1.2	7
588	Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. Journal of Clinical Lipidology, 2017, 11, 294-296.	0.6	7
589	Clinical utility gene card for: Tangier disease. European Journal of Human Genetics, 2017, 25, e1-e3.	1.4	7
590	Recent Advances in the Genetics of Atherothrombotic Disease and Its Determinants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e158-e166.	1.1	7
591	Nutraceuticals in endocrine disorders. Nature Reviews Endocrinology, 2018, 14, 68-70.	4.3	7
592	Genetic Variation in the Ontario Neurodegenerative Disease Research Initiative. Canadian Journal of Neurological Sciences, 2019, 46, 491-498.	0.3	7
593	Multisystem Progeroid Syndrome With Lipodystrophy, Cardiomyopathy, and Nephropathy Due to an LMNA p.R349W Variant. Journal of the Endocrine Society, 2020, 4, bvaa104.	0.1	7
594	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. Canadian Journal of Cardiology, 2022, 38, 311-319.	0.8	7

#	Article	IF	Citations
595	Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2022, 10, 142-148.	5.5	7
596	Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY). Clinical and Investigative Medicine, 2004, 27, 135-41.	0.3	7
597	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in Therapy, 2022, 39, 1857-1870.	1.3	7
598	Lipid-Modifying Therapies and Stroke Prevention. Current Neurology and Neuroscience Reports, 2022, 22, 375-382.	2.0	7
599	Allele Frequencies of Apolipoprotein A-I and A-II Gene Locus DNA Polymorphisms in Boston-Based Whites. Human Heredity, 1989, 39, 174-178.	0.4	6
600	Human cathepsin S gene (CTSS) promoter â^'25G/A polymorphism. Journal of Human Genetics, 2000, 45, 94-95.	1.1	6
601	The Metabolic Syndrome in Inuit. Diabetes Care, 2004, 27, 1517-1518.	4.3	6
602	Identification of a dysfunctional missense single nucleotide variant of human adenylyl cyclase VI. Clinical Pharmacology and Therapeutics, 2005, 77, 271-278.	2.3	6
603	Copy-number variations add a new layer of complexity in the human genome. Cmaj, 2007, 176, 441-442.	0.9	6
604	Phenomics, Lamin A/C, and Metabolic Disease. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4566-4568.	1.8	6
605	Update on the Genetics of Stroke and Cerebrovascular Disease 2007. Stroke, 2008, 39, 252-254.	1.0	6
606	Genome-Wide Association Studies of Plasma Lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2084-2086.	1.1	6
607	Translating genomic analyses into improved management of coronary artery disease. Future Cardiology, 2010, 6, 507-521.	0.5	6
608	Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation. Journal of Clinical Lipidology, 2010, 4, 310-313.	0.6	6
609	Infantile Sialic Acid Storage Disease: Two Unrelated Inuit Cases Homozygous for a Common Novel SLC17A5 Mutation. JIMD Reports, 2013, 12, 79-84.	0.7	6
610	Sequencing: The Next Generationâ€"What Is the Role of Whole-Exome Sequencing in the Diagnosis of Familial Cardiovascular Diseases?. Canadian Journal of Cardiology, 2014, 30, 152-154.	0.8	6
611	ARHGEF28 p.Lys280Metfs40Ter in an amyotrophic lateral sclerosis family with a C9orf72 expansion. Neurology: Genetics, 2017, 3, e190.	0.9	6
612	A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation. Endocrine Pathology, 2018, 29, 374-379.	5.2	6

#	Article	IF	Citations
613	LDL cholesterol: lower, faster, younger?. Lancet Diabetes and Endocrinology,the, 2020, 8, 5-7.	5.5	6
614	Ancestry-specific profiles of genetic determinants of severe hypertriglyceridemia. Journal of Clinical Lipidology, 2021, 15, 88-96.	0.6	6
615	What Is the Prevalence of Familial Hypercholesterolemia?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2629-2631.	1.1	6
616	Hepatic lipase deficiency in a Middle-Eastern-Arabic male. BMJ Case Reports, 2010, 2010, bcr1220092589-bcr1220092589.	0.2	6
617	Lamin A/C missense variants: from discovery to functional validation. Npj Genomic Medicine, 2021, 6, 102.	1.7	6
618	Case Report: Heterogeneity of Aldolase B in Hereditary Fructose Intolerance. American Journal of the Medical Sciences, 1991, 302, 364-368.	0.4	5
619	Uncovering Rare Mutations: An Unforeseen Complication of Routine Genotyping of APOE. Clinical Chemistry, 1999, 45, 1579-1581.	1.5	5
620	Functional promoter polymorphism in SREBP cleavage-activating protein (SCAP). Journal of Human Genetics, 2002, 47, 492-496.	1.1	5
621	Maturity-Onset Diabetes of the Young (MODY) Mutation in Type 2 Diabetes and Latent Autoimmune Diabetes of the Adult. Diabetes Care, 2003, 26, 3358-3359.	4.3	5
622	Synergism between mutant HNF1A and the metabolic syndrome in Oji-Cree Type 2 diabetes. Diabetic Medicine, 2005, 22, 1510-1515.	1.2	5
623	Genetic Forms of the Cardiometabolic Syndrome: What Can They Tell the Clinician?. Journal of the Cardiometabolic Syndrome, 2007, 2, 45-48.	1.7	5
624	Association of the FABP2 T54 Variant with Plasma Triglycerides and Insulin Resistance in a Multiethnic Population. Clinical Chemistry, 2008, 54, 1742-1744.	1.5	5
625	Lessons from Genetic Studies in Native Canadian Populations. Nutrition Reviews, 2009, 57, 43-50.	2.6	5
626	Letter to the editor. Canadian Journal of Cardiology, 2009, 25, 453.	0.8	5
627	Rare ATGL haplotypes are associated with increased plasma triglyceride concentrations in the Greenland Inuit. International Journal of Circumpolar Health, 2010, 69, 3-12.	0.5	5
628	A novel mutation of apolipoprotein B in a French Canadian family with homozygous hypobetalipoproteinemia. Journal of Clinical Lipidology, 2011, 5, 414-417.	0.6	5
629	Bias due to selection of rare variants using frequency in controls. Nature Genetics, 2011, 43, 394-395.	9.4	5
630	Gene Therapy for Hypercholesterolemia. Circulation Research, 2014, 115, 542-545.	2.0	5

#	Article	IF	Citations
631	PCSK9 inhibitors in familial hypercholesterolemia:ÂWhat is the evidence?. Journal of Clinical Lipidology, 2018, 12, 1106-1108.	0.6	5
632	Lipids and cardiovascular disease. Pathology, 2019, 51, 129-130.	0.3	5
633	Failure of cosegregation between a rare STAP1 missense variant and hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 636-638.	0.6	5
634	Role of Common Genetic Variation in Lone Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, e003179.	1.6	5
635	Evaluating Polygenic Risk Scores in â€œLoneâ€•Atrial Fibrillation. CJC Open, 2021, 3, 751-757.	0.7	5
636	Carotid Ultrasound in One, Two and Three Dimensions. Vascular Disease Prevention, 2005, 2, 87-91.	0.2	5
637	Advances in the care of lipodystrophies. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 152-160.	1.2	5
638	Genetic diagnosis of familial hypercholesterolemia in affected relatives using pedigree tracing. Clinical Biochemistry, 1996, 29, 371-377.	0.8	4
639	Allele Frequencies for Candidate Genes in Atherosclerosis and Diabetes among Trinidadian Neonates. Human Biology, 2001, 73, 525-531.	0.4	4
640	Survival in Academy Awardâ€“Winning Actors and Actresses. Annals of Internal Medicine, 2003, 138, 77.	2.0	4
641	Venn analysis as part of a bioinformatic approach to prioritize expressed sequence tags from cardiac libraries. Clinical Biochemistry, 2004, 37, 953-960.	0.8	4
642	Gene Therapy With Lipoprotein Lipase Variant S447X. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e25; author reply e25-8.	1.1	4
643	Familial hypobetalipoproteinemia due to a novel early stop mutation. Journal of Clinical Lipidology, 2008, 2, 384-390.	0.6	4
644	Triple X syndrome in a patient with partial lipodystrophy discovered using a high-density oligonucleotide microarray: a case report. Journal of Medical Case Reports, 2009, 3, 8867.	0.4	4
645	Clinical Implications of Direct-to-Consumer Genetic Testing for Cardiovascular Disease Risk. Canadian Journal of Cardiology, 2011, 27, 682-684.	0.8	4
646	Lipoprotein and Lipid Metabolism. , 2013, , 1-33.		4
647	Incremental Lowering of Low-Density Lipoprotein Cholesterol With Ezetimibe 20 mg vs 10 mg Daily in Patients Receiving Concomitant Statin Therapy. Canadian Journal of Cardiology, 2013, 29, 1395-1399.	0.8	4
648	The Metabolic Syndrome. , 2013, , 1006-1016.		4

#	Article	IF	Citations
649	Incident Diabetes With Statins: Biology, Artifact, or Both?. Canadian Journal of Cardiology, 2015, 31, 963-965.	0.8	4
650	Finding the Therapeutic Sweet Spot. Circulation: Cardiovascular Genetics, 2015, 8, 637-639.	5.1	4
651	Integrated Measure for Atherogenic Lipoproteins in the Modern Era. Journal of the American College of Cardiology, 2016, 67, 202-204.	1.2	4
652	Insulin affordability. Lancet Diabetes and Endocrinology,the, 2017, 5, 324.	5.5	4
653	Treatment of Severe Hypercholesterolemia in a Woman With Advanced Primary Sclerosing Cholangitis. JAMA Cardiology, 2017, 2, 575.	3.0	4
654	Whole-exome sequencing identifies a novel IHH insertion in an Ontario family with brachydactyly type A1. SAGE Open Medical Case Reports, 2018, 6, 2050313X1881871.	0.2	4
655	Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 959-961.	0.8	4
656	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. Journal of Clinical Lipidology, 2018, 12, 1146-1150.	0.6	4
657	Clinical Utility and Practical Considerations of a Coronary Artery Disease Genetic Risk Score. CJC Open, 2019, 1, 69-75.	0.7	4
658	Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab. Journal of Clinical Lipidology, 2019, 13, 411-414.	0.6	4
659	Apolipoprotein B and PNPLA3 Double Heterozygosity in a Fatherâ€“Son Pair With Advanced Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 383-385.	3.6	4
660	A cautionary tale: Is this APOB whole-gene duplication actually pathogenic?. Journal of Clinical Lipidology, 2020, 14, 631-635.	0.6	4
661	Familial Chylomicronemia Syndrome With a Novel Homozygous LPL Mutation Identified in Three Siblings in Their 50s. Annals of Internal Medicine, 2020, 172, 500.	2.0	4
662	Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 Mutation. Case Reports in Endocrinology, 2020, 2020, 1-6.	0.2	4
663	Liver Injury Associated With Ezetimibe Monotherapy. CJC Open, 2021, 3, 195-197.	0.7	4
664	Clinical and Mutation Spectra of Cockayne Syndrome in India. Neurology India, 2021, 69, 362.	0.2	4
665	Evidence of synergism among three genetic variants in a patient with LMNA-related lipodystrophy and amyotrophic lateral sclerosis leading to a remarkable nuclear phenotype. Molecular and Cellular Biochemistry, 2021, 476, 2633-2650.	1.4	4
666	Discussing polygenic risk with lipid clinic patients. Current Opinion in Lipidology, 2021, Publish Ahead of Print, 273-275.	1.2	4

#	Article	IF	Citations
667	Disorders of Lipoprotein Metabolism. , 2014, , 671-689.		4
668	Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab. CJC Open, 2022, 4, 347-349.	0.7	4
669	Caveolar dysfunction and lipodystrophies. European Journal of Endocrinology, 2022, 186, C1-C4.	1.9	4
670	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100216.	2.0	4
671	Variation within intron 3 of the apolipoprotein Cll gene. Nucleic Acids Research, 1991, 19, 3162-3162.	6.5	3
672	Molecular basis and allele specific screening of apolipoprotein CIISt. Michael. Clinical Biochemistry, 1992, 25, 309-312.	0.8	3
673	Longitudinal Differences in Familial Combined Hyperlipidemia Quantitative Trait Loci. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e120.	1.1	3
674	A Multiplex Human Syndrome Implicates a Key Role for Intestinal Cell Kinase in Development of Central Nervous, Skeletal, and Endocrine Systems. American Journal of Human Genetics, 2009, 84, 822.	2.6	3
675	Progression to Hepatitis and Fibrosis Secondary to Lomitapide Useâ€"Reply. JAMA Internal Medicine, 2014, 174, 1522.	2.6	3
676	PCSK9 inhibition and diabetes: turning to Mendel for clues. Lancet Diabetes and Endocrinology,the, 2017, 5, 78-79.	5.5	3
677	Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?. Canadian Journal of Cardiology, 2018, 34, 546-551.	0.8	3
678	Learning From Patients With Ultrarare Conditions. Journal of the American College of Cardiology, 2018, 71, 289-291.	1.2	3
679	Secondary causes of chylomicronemia: defining the underside of the iceberg. Journal of Internal Medicine, 2018, 283, 405-407.	2.7	3
680	Recent Highlights of ATVB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e185-e197.	1.1	3
681	Response by Daugherty et al to Letter Regarding Article, â€œConsideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies: A Statement From the Arteriosclerosis, Thrombosis, and Vascular Biology Councilâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e101-e102.	1.1	3
682	A tip of the CAP1 to cholesterol metabolism. European Heart Journal, 2019, 41, 253-254.	1.0	3
683	Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers. Clinical Therapeutics, 2019, 41, 2500-2516.	1.1	3
684	A novel homozygous variant in REN in a family presenting with classic features of disorders involving the reninâ€"angiotensin pathway, without renal tubular dysgenesis. American Journal of Medical Genetics, Part A, 2020, 182, 2284-2290.	0.7	3

#	Article	IF	Citations
685	Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia. Atherosclerosis, 2020, 304, 39-43.	0.4	3
686	Triglyceride-rich particles: new actors in valvular aortic stenosis. European Heart Journal, 2020, 41, 2300-2303.	1.0	3
687	Editorial comment: when Mendelian randomization goes astray. Current Opinion in Lipidology, 2021, 32, 79-80.	1.2	3
688	Novel PPARG mutation in multiple family members with chylomicronemia. Journal of Clinical Lipidology, 2021, 15, 431-434.	0.6	3
689	Lipoprotein(a) and Plasminogen: Linkage Analysis. , 1990, , 129-139.		3
690	Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins. Journal of Clinical Lipidology, 2022, 16, 155-159.	0.6	3
691	Great Chinese Famine and the Effects on Cardiometabolic Health for Future Generations. Hypertension, 2022, 79, 532-535.	1.3	3
692	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	0.6	3
693	Is it time to measure Lp(a) as part of coronary heart disease risk assessment?. Clinical Biochemistry, 1997, 30, 443-445.	0.8	2
694	Polymorphisms in the gene encoding phosphatidylserine-specific phospholipase A1 (PSPLA1). Journal of Human Genetics, 2002, 47, 0611-0613.	1.1	2
695	Treatment of partial lipodystrophy: can the zebra teach us about the horse?. Drug Discovery Today Disease Mechanisms, 2004, 1, 195-203.	0.8	2
696	Update on the Genetics of Stroke and Cerebrovascular Disease 2008. Stroke, 2009, 40, e289-91.	1.0	2
697	Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. Expert Opinion on Pharmacotherapy, 2011, 12, 675-678.	0.9	2
698	Doctor My Eyes: A Statin-Cataract Connection?. Canadian Journal of Cardiology, 2014, 30, 1508-1510.	0.8	2
699	Treatment of severe hypertriglyceridaemia â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 860-861.	5.5	2
700	Antisenses working overtime in lipids. Nature Reviews Endocrinology, 2015, 11, 574-576.	4.3	2
701	Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?. Canadian Journal of Cardiology, 2016, 32, 598-602.	0.8	2
702	Proprietary Considerations in the Use of Cardiovascular Genetic Data. Canadian Journal of Cardiology, 2016, 32, 1297-1299.	0.8	2

#	Article	IF	Citations
703	Bioinformatic detection of copy number variation in HNF4A causing maturity onset diabetes of the young. Clinical Genetics, 2019, 96, 376-377.	1.0	2
704	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC Open, 2019, 1, 190-197.	0.7	2
705	Severe Combined Dyslipidemia With a Complex Genetic Basis. Journal of Investigative Medicine High Impact Case Reports, 2019, 7, 232470961987705.	0.3	2
706	Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism. Journal of Clinical Densitometry, 2019, 22, 125-149.	0.5	2
707	Simplifying Detection of Copy-Number Variations in Maturity-Onset Diabetes of the Young. Canadian Journal of Diabetes, 2021, 45, 71-77.	0.4	2
708	Abetalipoproteinemia Due to a Novel Splicing Variant in MTTP in 3 Siblings. Journal of Investigative Medicine High Impact Case Reports, 2021, 9, 232470962110224.	0.3	2
709	Lipoprotein and Lipid Metabolism. , 2021, , 235-278.		2
710	Editorial comment: hazards of interpreting genetic reports. Current Opinion in Lipidology, 2021, 32, 81-82.	1.2	2
711	Apolipoprotein genetic variants and hereditary amyloidosis. Current Opinion in Lipidology, 2021, 32, 132-140.	1.2	2
712	Hoofbeats, zebras, and insights into insulin resistance. Journal of Clinical Investigation, 2009, 119, 249-51.	3.9	2
713	DNA sequencing in familial hypercholesterolaemia: the next generation. European Journal of Preventive Cardiology, 2021, 28, 873-874.	0.8	2
714	Web of Scienceâ€™s Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 367-371.	1.1	2
715	Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease. Mutation Research - Mutation Research Genomics, 1997, 382, 57-65.	1.2	1
716	Genetic prediction of coronary heart disease: Lessons from Canada. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 153-167.	0.6	1
717	Human hepatocyte nuclear factor-1Î² (HNF1B) 1968A/G polymorphism. Journal of Human Genetics, 2000, 45, 98-99.	1.1	1
718	Erratum to â€œDifferences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensionsâ€•[Atherosclerosis 178(2) (2005) 319â€“325]. Atherosclerosis, 2005, 182, 379-380.	0.4	1
719	Response to Landires et al.. Clinical Genetics, 2007, 71, 594-596.	1.0	1
720	The application of gene therapy in lipid disorders: where are we now?. Clinical Lipidology, 2012, 7, 419-429.	0.4	1

#	Article	IF	Citations
721	CETP Inhibitors: Will They Live up to Their Promise?. Current Cardiovascular Risk Reports, 2012, 6, 4-11.	0.8	1
722	DyslipidÃ©mie. Canadian Journal of Diabetes, 2013, 37, S484-S491.	0.4	1
723	Progress in genetics of plasma lipids. Current Opinion in Lipidology, 2014, 25, 99-101.	1.2	1
724	The Sum of Its Parts: The Polygenic Basis of Coronary Artery Disease. Canadian Journal of Cardiology, 2016, 32, 1372-1374.	0.8	1
725	PCSK9 inhibitors: smooth sailing or a little turbulence ahead?. Lancet Diabetes and Endocrinology,the, 2017, 5, 490-492.	5.5	1
726	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. Expert Opinion on Orphan Drugs, 2017, 5, 411-420.	0.5	1
727	Seeking â€˜meta guidelinesâ€™ for lipids. European Journal of Preventive Cardiology, 2017, 24, 72-75.	0.8	1
728	Statin therapy: time for a precision medicine approach?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 187-192.	0.4	1
729	Fatty liver in a non-obese patient. Paediatrics and Child Health, 2017, 22, 59-60.	0.3	1
730	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. Canadian Journal of Cardiology, 2018, 34, 532-535.	0.8	1
731	Can one overcome â€œunhealthy genesâ€?. Npj Genomic Medicine, 2019, 4, 24.	1.7	1
732	Ischemic Event Reduction and Triglycerides. Journal of the American College of Cardiology, 2019, 74, 1848-1849.	1.2	1
733	Regression of Xanthelasmas With Statin Treatment in a Normolipidemic Patient. Annals of Internal Medicine, 2020, 172, 701-702.	2.0	1
734	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. CJC Open, 2020, 2, 625-631.	0.7	1
735	Primary Aldosteronism in Hypertension: More Than a Factoid. Canadian Journal of Cardiology, 2021, 37, 196-198.	0.8	1
736	Preprint servers in lipidology. Current Opinion in Lipidology, 2021, Publish Ahead of Print, .	1.2	1
737	The Canadian Consensus Working Groupâ€™s Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. Contemporary Cardiology, 2020, , 137-150.	0.0	1
738	Expanding the phenotypic and molecular spectrum of NFS1 â€related disorders that cause functional deficiencies in mitochondrial and cytosolic ironâ€“sulfur cluster containing enzymes. Human Mutation, 2022, 43, 305-315.	1.1	1

#	Article	IF	Citations
739	A possible escape phenomenon of lipoprotein(a) in sustained plasma exchange. Transfusion Science, 1993, 14, 417-421.	0.6	0
740	1.P.247 Apolipoprotein ER112; R251G: A carboxy-terminal variant associated with hyperlipidemia and vascular disease. Atherosclerosis, 1997, 134, 68-69.	0.4	0
741	1.P.292 Genetic variation in factor VII associated with variation in plasma lipoprotein(a) concentration. Atherosclerosis, 1997, 134, 78.	0.4	0
742	Genetics in childhood atherosclerosis. Progress in Pediatric Cardiology, 1998, 9, 213-224.	0.2	0
743	RECIPIENT ANGIOTENSINOGEN GENE VARIANTS BUT NOT THE ACE INSERTION/DELETION POLYMORPHISM PREDICT RATE OF DECLINE IN RENAL ALLOGRAFT FUNCTION.. Transplantation, 2000, 69, S400-S401.	0.5	0
744	Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol. Clinical Biochemistry, 2002, 35, 341-346.	0.8	0
745	Is regression of coronary atherosclerosis possible by infusing recombinant apolipoprotein A-I?. Cmaj, 2004, 170, 954-954.	0.9	0
746	NPC1L1: from drug target to physiological sterol transporter. Future Lipidology, 2006, 1, 247-249.	0.5	0
747	Treating hypertriglyceridemia. Cmaj, 2007, 177, 604.2-605.	0.9	0
748	Lipid-altering gene variants and cardiovascular risk in the older population. Clinical Lipidology, 2009, 4, 721-724.	0.4	0
749	Genetic risk factors for stroke in the genome-wide association era. Expert Opinion on Medical Diagnostics, 2011, 5, 75-84.	1.6	0
750	Genetics and molecular biology. Current Opinion in Lipidology, 2012, 23, 83-84.	1.2	0
751	Editorial comment. Current Opinion in Lipidology, 2013, 24, 109-110.	1.2	0
752	Is Plant-Based Cardioprotection Evidence-Based?. Canadian Journal of Cardiology, 2014, 30, 1142-1144.	0.8	0
753	The Effect of Infrequent Low-Dose Rosuvastatin on the LipidÂProfile. Canadian Journal of Cardiology, 2014, 30, 1392-1395.	0.8	0
754	Inducing thyrotoxicosis in the liver to treat raised cholesterol. Lancet Diabetes and Endocrinology,the, 2014, 2, 438-439.	5.5	0
755	MG-107â€...Congenital sucrase-isomaltase deficiency: Identification of the common inuit founder mutation. Journal of Medical Genetics, 2015, 52, A1.3-A2.	1.5	0
756	MG-137â€...Autosomal recessive disorders are common in the old order amish population of southwestern ontario. Journal of Medical Genetics, 2015, 52, A10.1-A10.	1.5	0

#	Article	IF	Citations
757	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, S773.	0.2	0
758	Genetic studies in definite/probable FH in Argentina. Atherosclerosis, 2017, 263, e62.	0.4	0
759	Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5. Atherosclerosis, 2017, 263, e230.	0.4	0
760	Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR. Atherosclerosis, 2017, 263, e230.	0.4	0
761	Use of next-generation sequencing to detect copy number variations in the molecular diagnosis of familial hypercholesterolemia. Atherosclerosis, 2017, 263, e236.	0.4	0
762	Cover Image, Volume 177B, Number 1, January 2018. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, i.	1.1	0
763	Copy-number variation (CNVs) in Hypertriglyceridemia Patients. Atherosclerosis Supplements, 2018, 32, 50.	1.2	0
764	Update on the Familial Hypercholesterolemia Canada (FH Canada) Registry. Atherosclerosis Supplements, 2018, 32, 51-52.	1.2	0
765	To PLEX or not to PLEX: Managing Hypertriglyceridemia-associated Pancreatitis. Atherosclerosis Supplements, 2018, 32, 148.	1.2	0
766	LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. Atherosclerosis Supplements, 2018, 32, 153-154.	1.2	0
767	Connecting Extreme Ends of the Spectrum: Ultra-rare Androgen Receptor Mutations in Metabolic Phenotypes. Atherosclerosis Supplements, 2018, 32, 81.	1.2	0
768	Research digest: observing risks and benefits of diet and supplements. Lancet Diabetes and Endocrinology,the, 2019, 7, 752.	5.5	0
769	Research digest: seeking new lipid drug targets. Lancet Diabetes and Endocrinology,the, 2019, 7, 594.	5.5	0
770	From Laundry List to Rating Scheme. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1018-1019.	1.1	0
771	Comment on â€œA New Allelic Variant in the PANK2 Gene in a Patient with Incomplete HARP Syndromeâ€• Journal of Movement Disorders, 2021, 14, 254-255.	0.7	0
772	Decreased Abdominal Girth and Increased Blood Pressure Associated With a Single Nucleotide Variant of Human Adenylyl Cyclase 6. FASEB Journal, 2007, 21, A795.	0.2	0
773	Genetics of Metabolic Syndrome and Genetic Lipodystrophies. , 2009, , 63-81.		0
774	Restriction Isotyping of Apolipoprotein E. Annals of Internal Medicine, 1995, 122, 68.	2.0	0

#	Article	IF	Citations
775	27-OR: Simplifying Detection of Large Scale Deletions Causing MODY5. Diabetes, 2019, 68, 27-OR.	0.3	0
776	Integrated Analysis of the Pancreas and Islets Reveals Unexpected Findings in Human Male With Type 1 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab162.	0.1	0
777	Is it safe to deprescribe ezetimibe in familial hypercholesterolemia patients taking evolocumab?. CJC Open, 2021, 4, 428-431.	0.7	0
778	Rapidly lowering triglyceride levels by plasma exchange in acute pancreatitis: What's the point?. Journal of Clinical Apheresis, 2022, 37, 194-196.	0.7	0
779	Preventing cardiovascular events in patients with inflammatory arthritis: are we missing the mark?. Canadian Journal of Cardiology, 2022, , .	0.8	0